HKEX: 2171
Resignation of non-executive director and non-compliance with rule 3.21 of the listing rules
View original source (HKEXnews)Company analysis
Earlier from Carsgen Therapeutics
- Voluntary announcement - first patient dose of ct1190b in china phase i registrational trial
- CARsgen Therapeutics Announces 2026 Interim Results
- CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
- CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026